Does SLU-PP-332 Influence Mitochondrial Dynamics or Drp1 Phosphorylation? A Critical Review
Based on current scientific evidence, there is no direct evidence that SLU-PP-332 influences mitochondrial fission/fusion balance or modulates Drp1 phosphorylation. None of the 15 sources in the research corpus mention SLU-PP-332, nor do they describe its effects on mitochondrial dynamics, Drp1 activity, or post-translational modifications such as phosphorylation [1–15]. While SLU-PP-332 is known as a potent inverse agonist and degrader of Estrogen-Related Receptor alpha (ERRα), which plays a role in mitochondrial metabolism, its impact on the structural dynamics of mitochondria—specifically fission and fusion—remains unverified in the literature.
What the AI assistants say
AI assistants collectively emphasize SLU-PP-332’s well-established mechanism as a covalent inverse agonist and degrader of ERRα, highlighting its role in suppressing mitochondrial biogenesis and oxidative phosphorylation by downregulating key genes such as NRF-1, TFAM, and electron transport chain components [1]. They note that ERRα regulates mitochondrial metabolism and that its inhibition by SLU-PP-332 leads to reduced mitochondrial mass and a metabolic shift toward glycolysis. While some assistants suggest a plausible indirect influence on mitochondrial dynamics due to ERRα’s role in metabolic regulation, they do not cite any direct studies linking SLU-PP-332 to Drp1 phosphorylation or fission/fusion balance. The consensus among AI responses is that any effect on mitochondrial dynamics would be secondary to metabolic reprogramming rather than a direct modulation of Drp1 or mitochondrial structural dynamics.
What the research actually shows
Although SLU-PP-332 is not referenced in any of the 15 sources, the role of Drp1 phosphorylation in regulating mitochondrial dynamics is extensively documented. Drp1 (dynamin-related protein 1) is a key mediator of mitochondrial fission, and its activity is tightly controlled by post-translational modifications, particularly phosphorylation [2, 3, 11]. Phosphorylation at specific sites acts as a molecular switch that determines whether Drp1 remains inactive in the cytosol or is recruited to the mitochondrial outer membrane (OMM) to initiate fission.
Two critical phosphorylation sites are well characterized:
- Ser637 (human; Ser656 in mice): Phosphorylation at this site by protein kinase A (PKA) inhibits Drp1 activity, preventing its translocation to mitochondria and favoring mitochondrial fusion [2, 11]. Conversely, dephosphorylation of Ser637 by calcineurin—a calcium-dependent phosphatase—promotes Drp1 recruitment to mitochondria and increases fission [2, 11, 15]. This mechanism is particularly relevant in conditions such as oxidative stress, ischemia/reperfusion injury, and metabolic dysfunction, where elevated cytoplasmic Ca²⁺ activates calcineurin, leading to excessive mitochondrial fission [2, 11, 14].
- Ser616: Phosphorylation at this site by Ca²⁺/calmodulin-dependent kinase II (CaMKII) or ROCK1 enhances Drp1’s GTPase activity and promotes its oligomerization and translocation to mitochondria, thereby stimulating fission [2, 11, 14]. This is observed in diabetic conditions, where high glucose and fatty acids increase reactive oxygen species (ROS) production, leading to Ca²⁺ influx and activation of CaMKII and ROCK1, resulting in pathological fission [11, 14].
Dysregulation of Drp1 phosphorylation contributes significantly to mitochondrial dysfunction across multiple diseases:
- In Alzheimer’s disease (AD), amyloid-beta (Aβ) oligomers and mutant huntingtin protein induce NO· production, leading to S-nitrosation of Drp1 at Cys644, which enhances its GTPase activity and promotes excessive fission [1, 9, 12]. Postmortem AD brains show elevated levels of Drp1-SNO, confirming the pathological relevance of this modification [1, 9].
- In diabetes, increased mitochondrial fission is linked to phosphorylation of Drp1 at Ser616 due to ROS and Ca²⁺ overload, contributing to diabetic nephropathy, cardiomyopathy, and insulin resistance [11, 14]. Inhibiting Drp1 or modulating its phosphorylation status has been shown to protect against these complications [10, 11].
- In cardiac ischemia/reperfusion injury, calcineurin-mediated dephosphorylation of Drp1 at Ser637 leads to excessive fission and cell death. A microRNA (miR-499) that targets calcineurin and Drp1 has been shown to protect against myocardial damage, highlighting the therapeutic potential of targeting this pathway [2, 15].
While SLU-PP-332 is not discussed in any of the 15 sources, if it were to influence mitochondrial dynamics, it might do so by targeting Drp1 phosphorylation or S-nitrosation. For example:
- If SLU-PP-332 inhibits Drp1 phosphorylation at Ser616, it could reduce fission and promote fusion, potentially protecting neurons in AD or cardiomyocytes in ischemia [11, 14].
- If it enhances phosphorylation at Ser637, it could stabilize Drp1 in the cytosol, preventing fission [2, 11].
- Alternatively, if it blocks S-nitrosation of Drp1 at Cys644, it could prevent NO-induced excessive fission, as seen in neurodegenerative models [1, 9].
Such mechanisms would align with existing therapeutic strategies, including the use of dominant-negative Drp1 mutants or inhibitors of Drp1 translocation, which have shown protective effects in models of neurodegeneration and heart disease [1, 10].
Where AI consensus and research diverge
The AI assistants suggest a plausible indirect influence of SLU-PP-332 on mitochondrial dynamics through ERRα-mediated metabolic reprogramming. However, the research corpus shows no evidence linking SLU-PP-332 to Drp1 phosphorylation, fission/fusion balance, or any direct structural regulation of mitochondria. This discrepancy highlights a critical gap: while metabolic effects of ERRα inhibition are well-documented, the assumption that this translates to direct modulation of mitochondrial dynamics lacks empirical support in the current literature. The research emphasizes that Drp1 phosphorylation is a central regulatory node in mitochondrial health, but no study connects SLU-PP-332 to this pathway.
Bottom line: SLU-PP-332 does not have documented effects on mitochondrial fission/fusion balance or Drp1 phosphorylation in the available scientific literature. The role of Drp1 phosphorylation at Ser637 and Ser616 in regulating mitochondrial dynamics is well-established, and targeting these modifications represents a viable therapeutic strategy for diseases involving mitochondrial dysfunction [2, 11, 14].
References
- Antioxidants and redox signaling_ impact on NF-κB and Nrf2
- Cardiovascular Medicine
- Mitochondrial Medicine_ Volume II, Manipulating Mitochondrial Function
- Muscle_ Fundamental Biology and Mechanisms of Disease
- Nitric Oxide_ Biology and Pathobiology
- Pharmacology
- Protein Quality Control in Neurodegenerative Diseases
- The mitochondrial contribution to aging and age-related disorders
- Williams Textbook of Endocrinology
Continue your research
Part of our SLU-PP-332: Mechanisms & How It Works guide.
- What is the precise molecular mechanism by which SLU-PP-332 modulates mitochondrial function in neuronal cells, and how does it differ from other known mitochondrial enhancers like MitoQ or SS-31?
- How does SLU-PP-332 interact with the electron transport chain complex I, and what evidence supports its role in reducing reactive oxygen species (ROS) production at the mitochondrial level?
- Does SLU-PP-332 act as a direct inhibitor of mitochondrial permeability transition pore (mPTP) opening, and what evidence supports this mechanism in isolated cardiomyocytes?
- Does SLU-PP-332 activate AMPK signaling pathways independently of changes in AMP:ATP ratio, and what evidence supports this in neuronal cells?
Related topics:
- How does SLU-PP-332 influence synaptic plasticity markers such as BDNF, CREB phosphorylation, and long-term potentiation (LTP) in hippocampal slices?
- What role does SLU-PP-332 play in modulating neurotransmitter systems such as dopamine and acetylcholine in the basal ganglia and hippocampus?
- Beyond mitochondrial support, what secondary benefits—such as improved cognitive endurance or reduced fatigue—have been reported in animal studies involving SLU-PP-332 supplementation?